Korea United Pharmaceutical agreed to expand market to South America with Teva
On Mar 31, Korea United Pharmaceutical announced that they signed additional contract of Incrementally Modified Drug 'CLANZA CR Tab' in South American market with a global pharmaceutical company in Israel, Teva.
In Last February 2013, Korea United Pharmaceutical signed a contract with Teva and E...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
